Glutethimide

Glutethimide

Clinical data
Pregnancy category	C: (United States)
Routes of administration	oral
ATC code	N05CE01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) US: Schedule II Schedule III international
Pharmacokinetic data
Bioavailability	Variable
Metabolism	Hepatic
Elimination half-life	10-12 hours
Excretion	Renal:2% Fecal:2%
Identifiers
IUPAC name 3-ethyl-3-phenyl-piperidine-2,6-dione
CAS Number	77-21-4 Y
PubChem CID	3487
DrugBank	DB01437 Y
ChemSpider	3367 Y
UNII	C8I4BVN78E
KEGG	D00532 Y
ChEMBL	ChEMBL1102 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C13H15NO2
Molar mass	217.264 g/mol
3D model (JSmol)	Interactive image
SMILES O=C1NC(CCC1(CC)C2=CC=CC=C2)=O
InChI InChI=1S/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16) Y Key:JMBQKKAJIKAWKF-UHFFFAOYSA-N Y
(verify)

WikiDoc Resources for Glutethimide
Articles
Most recent articles on Glutethimide Most cited articles on Glutethimide Review articles on Glutethimide Articles on Glutethimide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Glutethimide Images of Glutethimide Photos of Glutethimide Podcasts & MP3s on Glutethimide Videos on Glutethimide
Evidence Based Medicine
Cochrane Collaboration on Glutethimide Bandolier on Glutethimide TRIP on Glutethimide
Clinical Trials
Ongoing Trials on Glutethimide at Clinical Trials.gov Trial results on Glutethimide Clinical Trials on Glutethimide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Glutethimide NICE Guidance on Glutethimide NHS PRODIGY Guidance FDA on Glutethimide CDC on Glutethimide
Books
Books on Glutethimide
News
Glutethimide in the news Be alerted to news on Glutethimide News trends on Glutethimide
Commentary
Blogs on Glutethimide
Definitions
Definitions of Glutethimide
Patient Resources / Community
Patient resources on Glutethimide Discussion groups on Glutethimide Patient Handouts on Glutethimide Directions to Hospitals Treating Glutethimide Risk calculators and risk factors for Glutethimide
Healthcare Provider Resources
Symptoms of Glutethimide Causes & Risk Factors for Glutethimide Diagnostic studies for Glutethimide Treatment of Glutethimide
Continuing Medical Education (CME)
CME Programs on Glutethimide
International
Glutethimide en Espanol Glutethimide en Francais
Business
Glutethimide in the Marketplace Patents on Glutethimide
Experimental / Informatics
List of terms related to Glutethimide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Glutethimide is a hypnotic sedative that was introduced by Ciba in 1954 as a safe alternative to barbiturates to treat insomnia. Before long, however, it had become clear that glutethimide was just as likely to cause addiction and caused similarly severe withdrawal symptoms. Doriden was the brand-name version of the drug; it was also available under the brand names Elrodorm, Noxyron, Glimid and others. Both the generic and brand-name forms are very rarely prescribed today. Current production levels in the United States (the annual quota for manufacturing imposed by the DEA has been three grams, enough for six Doriden tablets, for a number of years) point to it only being used in small scale research.

File:Glutethimide DOJ.jpg

Long term use

Long term use rebound effects, which resembled those seen in withdrawal, have anecdotally been described in patients who were still taking a stable dose of the drug. The symptoms included delirium, hallucinosis, convulsions and fever.

Recreational use

Glutethimide is a CYP2D6 enzyme inducer. When taken with codeine, it enables the body to convert higher amounts of the codeine (higher than the average 5 - 10%) to morphine. The general sedative effect also adds to the effect of the combination. The effect was also used clinically, including some research in the 1970s in various countries of using it under carefully monitored circumstances as a form of oral opioid agonist substitution therapy, e.g. as a Substitutionmittel that may be a useful alternative to methadone The combination was known as Dors & Fours, a Six Pack, Loads, etc. as two Doriden tablets and four Tylenol (or Emprin, Emprazil or other drugs) With Codeine No. 4, or plain 60 mg codeine tablets were sold as a set. The demand for this combination, in western Pennsylvania and surrounding areas of other states and perhaps elsewhere, has led to small-scale clandestine synthesis of glutethimide since 1984, a process that is, like methaqualone synthesis, somewhat difficult and fraught with potential bad outcomes when less-than-gifted chemists are doing the deed with industrial-grade precursors without adequate quality control. The fact that the simpler clandestine synthesis of other extinct pharmaceutical depressants like ethchlorvynol, methyprylon, or the oldest barbiturates is not reported would seem to point to a high level of motivation surrounding a unique drug, again much like methaqualone. Analysis of confiscated glutethimide seems to invariably show the drug or the results of attempted synthesis, whereas purported methaqualone is in a significant minority of cases found to be inert, or contain diphenhydramine or benzodiazepines

The enzyme induction is apparently several times stronger than that induced by promethazine (Phenergan, Atosil), a phenothiazine antihistamine used clinically as an opioid potentiator (Phenergan VC With Codeine, Mepergan (pethidine + promethazine), mixing the antihistamine with alphaprodine and other such drugs in an IV)

Legal status

Glutethimide is a Schedule II drug under the Convention on Psychotropic Substances. It was originally a Schedule III drug in the United States under the Controlled Substances Act, but in 1991 it was upgraded to Schedule II, after it was discovered that misuse combined with codeine increased the effect of the codeine and deaths had resulted from the combination. It has a DEA ACSCN of 2550 and a 2013 production quota of 3 g.

Chemistry

Glutethimide (2-ethyl-2-phenylgutarimide) is synthesized by addition of 2-phenylbutyronitrile to the methylacrylate (Michael reaction), and the subsequent alkaline hydrolysis of the nitrile group in the obtained compound into an amide group, and the subsequent acidic cyclization of the product into the desired glutethimide. The (R) isomer has a faster onset and more potent anticonvulsant activity in animal models than the (S) isomer.

File:Glutethimide syn.png

See also

• Aminoglutethimide
• Piperidione
• Pyrithyldione